The COVID-19 pandemic and associated declines in cancer incidence by race/ethnicity and census-tract level SES, rurality, and persistent poverty status.
Humans
COVID-19
/ epidemiology
Neoplasms
/ epidemiology
Incidence
United States
/ epidemiology
Female
Male
Poverty
/ statistics & numerical data
Social Class
Ethnicity
/ statistics & numerical data
SEER Program
Rural Population
/ statistics & numerical data
Health Status Disparities
SARS-CoV-2
Censuses
Pandemics
COVID‐19
cancer incidence
census tract‐level groups
health disparity
pandemic
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
Sep 2024
Sep 2024
Historique:
revised:
16
08
2024
received:
16
03
2024
accepted:
02
09
2024
medline:
15
9
2024
pubmed:
15
9
2024
entrez:
13
9
2024
Statut:
ppublish
Résumé
The COVID-19 pandemic had a significant impact on cancer screening and treatment, particularly in 2020. However, no single study has comprehensively analyzed its effects on cancer incidence and disparities among groups such as race/ethnicity, socioeconomic status (SES), persistent poverty (PP), and rurality. Utilizing the recent data from the United States National Cancer Institute's Surveillance, Epidemiology, and End Results Program, we calculated delay- and age-adjusted incidence rates for 13 cancer sites in 2020 and 2015-2019. Percent changes (PCs) of rates in 2020 compared to 2015-2019 were measured and compared across race/ethnic, census tract-level SES, PP, and rurality groups. Overall, incidence rates decreased from 2015-2019 to 2020, with varying PCs by cancer sites and population groups. Notably, NH Blacks showed significantly larger PCs than NH Whites in female lung, prostate, and colon cancers (e.g., prostate cancer: NH Blacks -7.3, 95% CI: [-9.0, -5.5]; NH Whites: -3.1, 95% CI: [-3.9, -2.2]). Significantly larger PCs were observed for the lowest versus highest SES groups (prostate cancer), PP versus non-PP groups (prostate and female breast cancer), and all urban versus rural areas (prostate, female breast, female and male lung, colon, cervix, melanoma, liver, bladder, and kidney cancer). The COVID-19 pandemic coincided with reduction in incidence rates in the U.S. in 2020 and was associated with worsening disparities among groups, including race/ethnicity, SES, rurality, and PP groups, across most cancer sites. Further investigation is needed to understand the specific effects of COVID-19 on different population groups of interest.
Sections du résumé
BACKGROUND
BACKGROUND
The COVID-19 pandemic had a significant impact on cancer screening and treatment, particularly in 2020. However, no single study has comprehensively analyzed its effects on cancer incidence and disparities among groups such as race/ethnicity, socioeconomic status (SES), persistent poverty (PP), and rurality.
METHODS
METHODS
Utilizing the recent data from the United States National Cancer Institute's Surveillance, Epidemiology, and End Results Program, we calculated delay- and age-adjusted incidence rates for 13 cancer sites in 2020 and 2015-2019. Percent changes (PCs) of rates in 2020 compared to 2015-2019 were measured and compared across race/ethnic, census tract-level SES, PP, and rurality groups.
RESULTS
RESULTS
Overall, incidence rates decreased from 2015-2019 to 2020, with varying PCs by cancer sites and population groups. Notably, NH Blacks showed significantly larger PCs than NH Whites in female lung, prostate, and colon cancers (e.g., prostate cancer: NH Blacks -7.3, 95% CI: [-9.0, -5.5]; NH Whites: -3.1, 95% CI: [-3.9, -2.2]). Significantly larger PCs were observed for the lowest versus highest SES groups (prostate cancer), PP versus non-PP groups (prostate and female breast cancer), and all urban versus rural areas (prostate, female breast, female and male lung, colon, cervix, melanoma, liver, bladder, and kidney cancer).
CONCLUSIONS
CONCLUSIONS
The COVID-19 pandemic coincided with reduction in incidence rates in the U.S. in 2020 and was associated with worsening disparities among groups, including race/ethnicity, SES, rurality, and PP groups, across most cancer sites. Further investigation is needed to understand the specific effects of COVID-19 on different population groups of interest.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e70220Informations de copyright
© 2024 Information Management Services, Inc. Cancer Medicine published by John Wiley & Sons Ltd. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
Références
World Health Organization. Coronavirus disease (COVID‐19) pandemic. 2024. Accessed February 26, 2024. https://www.who.int/europe/emergencies/situations/covid‐19
Julia Kravchenko MH, Akushevich I. Chronic conditions during the COVID pandemic: mortality patterns in the United States. Innov Aging. 2022;6(Suppl 1):257. doi:10.1093/geroni/igac059.1021
Fedewa SA, Star J, Bandi P, et al. Changes in cancer screening in the US during the COVID‐19 pandemic. JAMA Netw Open. 2022;5(6):e2215490. doi:10.1001/jamanetworkopen.2022.15490
Sabatino SA, Thompson TD, White MC, et al. Up‐to‐date breast, cervical, and colorectal cancer screening test use in the United States, 2021. Prev Chronic Dis. 2023;20:E94. doi:10.5888/pcd20.230071
Oakes AH, Boyce K, Patton C, Jain S. Rates of routine cancer screening and diagnosis before vs after the COVID‐19 pandemic. JAMA Oncologia. 2023;9(1):145‐146. doi:10.1001/jamaoncol.2022.5481
Semprini J, Ranganathan R. The 2020 US cancer screening deficit and the timing of adults' most recent screen: a population‐based cross‐sectional study. Fam Med Community Health. 2023;11(3):e001893. doi:10.1136/fmch-2022-001893
Patt D, Gordan L, Diaz M, et al. Impact of COVID‐19 on cancer care: how the pandemic is delaying cancer diagnosis and treatment for American seniors. JCO Clin Cancer Inform. 2020;4:1059‐1071. doi:10.1200/CCI.20.00134
Epic Research. Delayed cancer screenings. Epic Research. 2020.Accessed July 18, 2024. https://epicresearch.org/articles/delays‐in‐preventive‐cancer‐screenings‐during‐covid‐19‐pandemic
Mast C, del Rio AM. Delayed cancer screenings—a second look. Epic Research 2020. Accessed July 18, 2024. https://epicresearch.org/articles/delayed‐cancer‐screenings‐a‐second‐look
Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System. 2023. Accessed December 5, 2023. https://www.cdc.gov/brfss/index.html
Englum BR, Prasad NK, Lake RE, et al. Impact of the COVID‐19 pandemic on diagnosis of new cancers: a national multicenter study of the veterans affairs healthcare system. Cancer. 2022;128(5):1048‐1056. doi:10.1002/cncr.34011
Howlader N, Bhattacharya M, Scoppa S, et al. Cancer and COVID‐19: U.S. Cancer incidence rates during the first year of the pandemic. J Natl Cancer Inst. 2023;116:208‐215. doi:10.1093/jnci/djad205
Burus T, Lei F, Huang B, et al. Undiagnosed cancer cases in the US during the first 10 months of the COVID‐19 pandemic. JAMA Oncol. 2024;10(4):500‐507. doi:10.1001/jamaoncol.2023.6969
Andraska EA, Alabi O, Dorsey C, et al. Health care disparities during the COVID‐19 pandemic. Semin Vasc Surg. 2021;34(3):82‐88. doi:10.1053/j.semvascsurg.2021.08.002
Andrew L, Schmidt ZB, Bhalla S, et al. Cancer care disparities during the COVID‐19 pandemic: COVID‐19 and cancer outcomes study. Cancer Cell. 2020;38(6):769‐770. doi:10.1016/j.ccell.2020.10.023
Patel MI, Ferguson JM, Castro E, et al. Racial and ethnic disparities in cancer care during the COVID‐19 pandemic. JAMA Netw Open. 2022;5(7):e2222009. doi:10.1001/jamanetworkopen.2022.22009
Fu J, Reid SA, French B, et al. Racial disparities in COVID‐19 outcomes among black and White patients with cancer. JAMA Netw Open. 2022;5(3):e224304. doi:10.1001/jamanetworkopen.2022.4304
Semprini J, Pagedar NA, Boakye EA, Osazuwa‐Peters N. Head and neck cancer incidence in the United States before and during the COVID‐19 pandemic. JAMA Otolaryngol Head Neck Surg. 2024;150(3):193‐200. doi:10.1001/jamaoto.2023.4322
National Cancer Institute. Registry Groupings in SEER Data and Statistics. 2024. Accessed January 30, 2024. https://seer.cancer.gov/registries/terms.html
Natioanl Cancer Institute. Surveillance, Epidemiology, and End Results Program: Population Characteristics. 2024. Accessed June 21, 2024. https://seer.cancer.gov/registries/characteristics.html
Yu M, Tatalovich Z, Gibson JT, Cronin KA. Using a composite index of socioeconomic status to investigate health disparities while protecting the confidentiality of cancer registry data. Cancer Causes & Control: CCC. 2014;25(1):81‐92. doi:10.1007/s10552-013-0310-1
National Cancer Institute SEER Program. Incidence Data with Census Tract Attributes Database. 2023. Accessed December 14, 2023. https://seer.cancer.gov/seerstat/variables/countyattribs/census‐tract‐attribs.html
United States Census Bureau. 2010 Census urban and rural classification and urban area criteria. https://www.census.gov/programs‐surveys/geography/guidance/geo‐areas/urban‐rural/2010‐urban‐rural.html
Moss JL, Pinto CN, Srinivasan S, Cronin KA, Croyle RT. Enduring cancer disparities by persistent poverty, rurality, and race: 1990–1992 to 2014–2018. J Natl Cancer Inst. 2022;114(6):829‐836. doi:10.1093/jnci/djac038
National Cancer Institute. SEER*Stat Software. 2023. Accessed February 24, 2023. https://seer.cancer.gov/seerstat/
Tiwari RC, Clegg LX, Zou Z. Efficient interval estimation for age‐adjusted cancer rates. Stat Methods Med Res. 2006;15(6):547‐569. doi:10.1177/0962280206070621
National Cancer Institute. SEER*Stat Tutorials—Step 3: Calculating age‐adjusted rates. 2024. Accessed July 16, 2024. https://seer.cancer.gov/seerstat/tutorials/aarates/step3.html
Midthune DN, Fay MP, Clegg LX, Feuer EJ. Modeling reporting delays and reporting corrections in cancer registry data. J Am Stat Assoc. 2005;100(469):61‐70.
Schenker N, Gentleman JF. On judging the significance of differences by examining the overlap between confidence intervals. The Am Stat. 2001;55:182‐186. doi:10.1198/000313001317097960
Sharpless NE. COVID‐19 and cancer. Science. 2020;368(6497):1290. doi:10.1126/science.abd3377
Masterson JM, Luu M, Dallas KB, Daskivich LP, Spiegel B, Daskivich TJ. Disparities in COVID‐19 disease incidence by income and vaccination coverage—81 communities, Los Angeles, California, July 2020–September 2021. MMWR Morb Mortal Wkly Rep. 2023;72:728‐731. 10.15585/mmwr.mm7226a5
Moynihan R, Sanders S, Michaleff ZA, et al. Impact of COVID‐19 pandemic on utilisation of healthcare services: a systematic review. BMJ Open. 2021;11:e045343. doi:10.1136/bmjopen-2020-045343
Xiong J, Lipsitz O, Nasri F, et al. Impact of COVID‐19 pandemic on mental health in the general population: a systematic review. J Affect Disord. 2020;277:55‐64. doi:10.1016/j.jad.2020.08.001